Clinical Trials Browser

Recruiting × belzutifan × Genitourinary × Clear all

Carcinoma, Carcinoma, Renal Cell

NCT07405164 2026-04-17

MK-6482-043

Phase 3 Recruiting

450 enrolled

Genitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT07049926 2026-03-20

MK-3475-03C

Phase 1/2 Recruiting

140 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT02861573 2026-02-17

KEYNOTE-365

Phase 1/2 Recruiting

1,200 enrolled

Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT06234605 2026-01-15

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

Phase 1 Recruiting

80 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT07187778 2026-01-05

Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

Phase 2 Recruiting

10 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT07179770 2025-09-23

Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)

Phase 1 Recruiting

12 enrolled

Genitourinary

Clear-cell metastatic renal cell carcinoma

NCT07167329 2025-09-11

BELIEVE-VHL

Phase 2 Recruiting

100 enrolled

CNSEndocrineGenitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma, Neuroectodermal Tumors, Primitive, Hemangioblastoma

Clinical Trials

LITESPARK-033

MK-6482-043

MK-3475-03C

KEYNOTE-365

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)

BELIEVE-VHL